SNSS - Sunesis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 555.78M
Enterprise Value 366.59M
Trailing P/E N/A
Forward P/E 1-2.40
PEG Ratio (5 yr expected) 1-0.02
Price/Sales (ttm)
Price/Book (mrq)N/A
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-2.74

Trading Information

Stock Price History

Beta (3Y Monthly) 4.53
52-Week Change 3-56.39%
S&P500 52-Week Change 30.90%
52 Week High 32.2600
52 Week Low 30.2000
50-Day Moving Average 30.8017
200-Day Moving Average 30.9098

Share Statistics

Avg Vol (3 month) 31.02M
Avg Vol (10 day) 3229.74k
Shares Outstanding 5N/A
Float 57.09M
% Held by Insiders 10.31%
% Held by Institutions 149.97%
Shares Short (Jul 15, 2019) 4938.3k
Short Ratio (Jul 15, 2019) 40.63
Short % of Float (Jul 15, 2019) 41.61%
Short % of Shares Outstanding (Jul 15, 2019) 41.29%
Shares Short (prior month Jun 14, 2019) 41.11M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 26/1
Last Split Date 3Sep 8, 2016

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-55.50%
Return on Equity (ttm)-155.32%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)237k
EBITDA -24.3M
Net Income Avi to Common (ttm)-25.2M
Diluted EPS (ttm)-0.6030
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)24.81M
Total Cash Per Share (mrq)0.34
Total Debt (mrq)7.26M
Total Debt/Equity (mrq)42.48
Current Ratio (mrq)2.65
Book Value Per Share (mrq)-0.12

Cash Flow Statement

Operating Cash Flow (ttm)-23.97M
Levered Free Cash Flow (ttm)-14.64M